Overview

A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
A study to test the safety and effect of twice daily raltegravir in a diverse cohort of patients currently infected with human immunodeficiency virus (HIV), where at least 50% are African American and at least 25% are female, either having received antiretroviral drugs before or not.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Raltegravir Potassium